{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:55:48Z","timestamp":1794970548050,"version":"4.9.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine kinase inhibitors has demonstrated that targeting of prevalent FMS-related receptor tyrosine kinase 3 (FLT3) gain-of-function mutations can provide significant survival benefits for patients, although the efficacy of FLT3 inhibitors in eliminating FLT3-mutated clones is variable. We identified a T cell receptor (TCR) reactive to the recurrent D835Y driver mutation in the FLT3 tyrosine kinase domain (TCR<jats:sup>FLT3D\/Y<\/jats:sup>). TCR<jats:sup>FLT3D\/Y<\/jats:sup>-redirected T cells selectively eliminated primary human AML cells harboring the FLT3<jats:sup>D835Y<\/jats:sup> mutation in vitro and in vivo. TCR<jats:sup>FLT3D\/Y<\/jats:sup> cells rejected both CD34<jats:sup>+<\/jats:sup> and CD34<jats:sup>\u2212<\/jats:sup> AML in mice engrafted with primary leukemia from patients, reaching minimal residual disease-negative levels, and eliminated primary CD34<jats:sup>+<\/jats:sup> AML leukemia-propagating cells in vivo. Thus, T cells targeting a single shared mutation can provide efficient immunotherapy toward selective elimination of clonally involved primary AML cells in vivo.<\/jats:p>","DOI":"10.1038\/s43018-023-00642-8","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:02:13Z","timestamp":1696262533000},"page":"1474-1490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo"],"prefix":"10.1038","volume":"4","author":[{"given":"Eirini","family":"Giannakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Lehander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Virding Culleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-083X","authenticated-orcid":false,"given":"Terhi","family":"Karpanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuichi","family":"Yoshizato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even H.","family":"Rustad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Milek","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Chand","family":"Bollineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Delic-Sarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea Johanne","family":"Gjerdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolos","family":"Douvlataniotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarja","family":"Laos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-1545","authenticated-orcid":false,"given":"Amy","family":"Hillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Wai Loon","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Sejer\u00f8","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Kai","family":"Bentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4441","authenticated-orcid":false,"given":"Marieke","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-3659","authenticated-orcid":false,"given":"Sten Eirik W.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-2526","authenticated-orcid":false,"given":"Petter S.","family":"Woll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3100","authenticated-orcid":false,"given":"Johanna","family":"Olweus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1073\/pnas.92.17.7976","volume":"92","author":"PG Coulie","year":"1995","unstructured":"Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976\u20137980 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.7652577","volume":"269","author":"T Wolfel","year":"1995","unstructured":"Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281\u20131284 (1995).","journal-title":"Science"},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081\u20131091 (2012).","journal-title":"Cancer Res."},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"642_CR11","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3389\/fimmu.2017.01718","volume":"8","author":"T Karpanen","year":"2017","unstructured":"Karpanen, T. & Olweus, J. The potential of donor T-cell repertoires in neoantigen-targeted cancer immunotherapy. Front. Immunol. 8, 1718 (2017).","journal-title":"Front. Immunol."},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023).","journal-title":"Nature"},{"key":"642_CR13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"642_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim, S. P. et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol. Res. 10, 932\u2013946 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"642_CR15","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"642_CR16","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1182\/blood-2009-06-204669","volume":"114","author":"G Socie","year":"2009","unstructured":"Socie, G. & Blazar, B. R. Acute graft-versus-host disease: from the bench to the bedside. Blood 114, 4327\u20134336 (2009).","journal-title":"Blood"},{"key":"642_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana, S. & Gill, S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front. Oncol. 10, 697 (2020).","journal-title":"Front. Oncol."},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver, N., Alotaibi, A. S., Bucklein, V. & Subklewe, M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35, 1843\u20131863 (2021).","journal-title":"Leukemia"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian, S. S. et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29, 1637\u20131647 (2015).","journal-title":"Leukemia"},{"key":"642_CR20","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343\u20132354 (2014).","journal-title":"Blood"},{"key":"642_CR21","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","volume":"32","author":"H Jetani","year":"2018","unstructured":"Jetani, H. et al. CAR T-cells targeting FLT3 have potent activity against FLT3\u2212ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 32, 1168\u20131179 (2018).","journal-title":"Leukemia"},{"key":"642_CR22","doi-asserted-by":"publisher","first-page":"12551","DOI":"10.1073\/pnas.94.23.12551","volume":"94","author":"J Olweus","year":"1997","unstructured":"Olweus, J. et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl Acad. Sci. USA 94, 12551\u201312556 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"642_CR23","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453 (2018).","journal-title":"Cell"},{"key":"642_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner, S. et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33, 64\u201374 (2019).","journal-title":"Leukemia"},{"key":"642_CR25","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"642_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo, G. S., Estey, E. H. & Walter, R. B. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 28, 143\u2013153 (2014).","journal-title":"Blood Rev."},{"key":"642_CR27","doi-asserted-by":"crossref","unstructured":"Ali, M. et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat. Biotechnol. 40, 488\u2013498 (2021).","DOI":"10.1038\/s41587-021-01089-x"},{"key":"642_CR28","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064\u20131072 (2019).","journal-title":"Nat. Med."},{"key":"642_CR29","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","volume":"129","author":"DI van der Lee","year":"2019","unstructured":"van der Lee, D. I. et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J. Clin. Invest. 129, 774\u2013785 (2019).","journal-title":"J. Clin. Invest."},{"key":"642_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","volume":"5","author":"G Xie","year":"2021","unstructured":"Xie, G. et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat. Biomed. Eng. 5, 399\u2013413 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"642_CR31","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1172\/JCI137723","volume":"130","author":"MA Biernacki","year":"2020","unstructured":"Biernacki, M. A. et al. CBFB\u2013MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J. Clin. Invest. 130, 5127\u20135141 (2020).","journal-title":"J. Clin. Invest."},{"key":"642_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"642_CR33","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","volume":"125","author":"N Daver","year":"2015","unstructured":"Daver, N. et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 125, 3236\u20133245 (2015).","journal-title":"Blood"},{"key":"642_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone, R. M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454\u2013464 (2017).","journal-title":"N. Engl. J. Med."},{"key":"642_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith, C. C. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485, 260\u2013263 (2012).","journal-title":"Nature"},{"key":"642_CR36","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/leu.2015.165","volume":"29","author":"CC Smith","year":"2015","unstructured":"Smith, C. C., Lin, K., Stecula, A., Sali, A. & Shah, N. P. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 29, 2390\u20132392 (2015).","journal-title":"Leukemia"},{"key":"642_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","volume":"130","author":"CC Smith","year":"2017","unstructured":"Smith, C. C. et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood 130, 48\u201358 (2017).","journal-title":"Blood"},{"key":"642_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Stronen","year":"2016","unstructured":"Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337\u20131341 (2016).","journal-title":"Science"},{"key":"642_CR39","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","volume":"14","author":"M Ali","year":"2019","unstructured":"Ali, M. et al. Induction of neoantigen-reactive T cells from healthy donors. Nat. Protoc. 14, 1926\u20131943 (2019).","journal-title":"Nat. Protoc."},{"key":"642_CR40","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","volume":"66","author":"CJ Cohen","year":"2006","unstructured":"Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor activity of murine\u2013human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability. Cancer Res. 66, 8878\u20138886 (2006).","journal-title":"Cancer Res."},{"key":"642_CR41","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"642_CR42","doi-asserted-by":"publisher","first-page":"E10702","DOI":"10.1073\/pnas.1810653115","volume":"115","author":"MT Bethune","year":"2018","unstructured":"Bethune, M. T. et al. Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc. Natl Acad. Sci. USA 115, E10702\u2013E10711 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"642_CR43","doi-asserted-by":"publisher","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","volume":"9","author":"A Marcu","year":"2021","unstructured":"Marcu, A. et al. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J. Immunother. Cancer 9, e002071 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"642_CR44","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).","journal-title":"Science"},{"key":"642_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"642_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328\u2013333 (2014).","journal-title":"Nature"},{"key":"642_CR47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon, N. et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138\u2013152 (2011).","journal-title":"Cancer Cell"},{"key":"642_CR48","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"642_CR49","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"642_CR50","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis, G. J. et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131, 1275\u20131291 (2018).","journal-title":"Blood"},{"key":"642_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman, A. H. et al. Targeting public neoantigens for cancer immunotherapy. Nat. Cancer 2, 487\u2013497 (2021).","journal-title":"Nat. Cancer"},{"key":"642_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","volume":"41","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg, M. & Coukos, G. Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr. Opin. Immunol. 41, 9\u201317 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"642_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0636-8","volume":"11","author":"MW Loffler","year":"2019","unstructured":"Loffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 28 (2019).","journal-title":"Genome Med."},{"key":"642_CR54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1074-7613(00)80483-5","volume":"4","author":"Y Sykulev","year":"1996","unstructured":"Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J. & Eisen, H. N. Evidence that a single peptide\u2013MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565\u2013571 (1996).","journal-title":"Immunity"},{"key":"642_CR55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"642_CR56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"642_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"642_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"642_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"642_CR60","doi-asserted-by":"crossref","unstructured":"Lang, F., Schrors, B., Lower, M., Tureci, O. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","DOI":"10.1038\/s41573-021-00387-y"},{"key":"642_CR61","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"642_CR62","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","volume":"3","author":"BY Jin","year":"2018","unstructured":"Jin, B. Y. et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 3, e99488 (2018).","journal-title":"JCI Insight"},{"key":"642_CR63","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1084\/jem.20141308","volume":"211","author":"F Duan","year":"2014","unstructured":"Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231\u20132248 (2014).","journal-title":"J. Exp. Med."},{"key":"642_CR64","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946\u2013957 (2022).","journal-title":"Nat. Med."},{"key":"642_CR65","doi-asserted-by":"publisher","unstructured":"Foldvari Z, Knetter C, Yang W, et al. A systematic safety pipeline for selection of T-cell receptors to enter clinical use. NPJ Vaccines https:\/\/doi.org\/10.1038\/s41541-023-00713-y (2023).","DOI":"10.1038\/s41541-023-00713-y"},{"key":"642_CR66","doi-asserted-by":"publisher","first-page":"149ra18","DOI":"10.1126\/scitranslmed.3004315","volume":"4","author":"M Jan","year":"2012","unstructured":"Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra18 (2012).","journal-title":"Sci. Transl. Med."},{"key":"642_CR67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28, 345\u2013352 (2022).","journal-title":"Nat. Med."},{"key":"642_CR68","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41587-022-01282-6","volume":"40","author":"E Dolgin","year":"2022","unstructured":"Dolgin, E. First soluble TCR therapy opens \u2018new universe\u2019 of cancer targets. Nat. Biotechnol. 40, 441\u2013444 (2022).","journal-title":"Nat. Biotechnol."},{"key":"642_CR69","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/leu.2010.186","volume":"24","author":"IW Abrahamsen","year":"2010","unstructured":"Abrahamsen, I. W. et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 24, 1901\u20131909 (2010).","journal-title":"Leukemia"},{"key":"642_CR70","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1073\/pnas.1306549111","volume":"111","author":"S Kumari","year":"2014","unstructured":"Kumari, S. et al. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc. Natl Acad. Sci. USA 111, 403\u2013408 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"642_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nm1360","volume":"12","author":"M Toebes","year":"2006","unstructured":"Toebes, M. et al. Design and use of conditional MHC class I ligands. Nat. Med. 12, 246\u2013251 (2006).","journal-title":"Nat. Med."},{"key":"642_CR72","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nmeth.1345","volume":"6","author":"SR Hadrup","year":"2009","unstructured":"Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520\u2013526 (2009).","journal-title":"Nat. Methods"},{"key":"642_CR73","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/nm.3359","volume":"19","author":"C Linnemann","year":"2013","unstructured":"Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534\u20131541 (2013).","journal-title":"Nat. Med."},{"key":"642_CR74","doi-asserted-by":"publisher","first-page":"W503","DOI":"10.1093\/nar\/gkn316","volume":"36","author":"X Brochet","year":"2008","unstructured":"Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503\u2013W508 (2008).","journal-title":"Nucleic Acids Res."},{"key":"642_CR75","doi-asserted-by":"crossref","unstructured":"Toebes, M., Rodenko, B., Ovaa, H. & Schumacher, T. N. Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Protoc. Immunol. 87, 18.16.1\u201318.16.20 (2009).","DOI":"10.1002\/0471142735.im1816s87"},{"key":"642_CR76","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41592-018-0179-8","volume":"15","author":"K Sikorski","year":"2018","unstructured":"Sikorski, K. et al. A high-throughput pipeline for validation of antibodies. Nat. Methods 15, 909\u2013912 (2018).","journal-title":"Nat. Methods"},{"key":"642_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature25455","volume":"554","author":"J Carrelha","year":"2018","unstructured":"Carrelha, J. et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature 554, 106\u2013111 (2018).","journal-title":"Nature"},{"key":"642_CR78","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","volume":"25","author":"PS Woll","year":"2014","unstructured":"Woll, P. S. et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25, 794\u2013808 (2014).","journal-title":"Cancer Cell"},{"key":"642_CR79","doi-asserted-by":"publisher","first-page":"lqaa070","DOI":"10.1093\/nargab\/lqaa070","volume":"2","author":"T Gregory","year":"2020","unstructured":"Gregory, T. et al. Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. NAR Genom. Bioinform. 2, lqaa070 (2020).","journal-title":"NAR Genom. Bioinform."},{"key":"642_CR80","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1093\/nar\/gkt126","volume":"41","author":"Y Shiraishi","year":"2013","unstructured":"Shiraishi, Y. et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res. 41, e89 (2013).","journal-title":"Nucleic Acids Res."},{"key":"642_CR81","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"642_CR82","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato, T. et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129, 2347\u20132358 (2017).","journal-title":"Blood"},{"key":"642_CR83","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3324\/haematol.2015.141796","volume":"101","author":"R Rampal","year":"2016","unstructured":"Rampal, R. & Figueroa, M. E. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica 101, 672\u2013679 (2016).","journal-title":"Haematologica"},{"key":"642_CR84","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"N Jain","year":"2023","unstructured":"Jain, N. et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 615, 315\u2013322 (2023).","journal-title":"Nature"},{"key":"642_CR85","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"642_CR86","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/leu.2017.48","volume":"31","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia 31, 2029\u20132036 (2017).","journal-title":"Leukemia"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00642-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T23:03:30Z","timestamp":1698188610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00642-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":86,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00642-8","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application has been filed by the Oslo University Hospital institutional technology transfer office Inven2 protecting the TCR sequence (J.O. and E.G. are inventors). J.O. is on the scientific advisory board of Asgard Therapeutics and is a cofounder of T-Rx therapeutics, a company that aims to develop TCR T cell therapies. The other co-authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}